SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field…
Top-line results from AURORA, the placebo-controlled phase 2 study of bitopertin in erythropoietic porphyrias (EPP), expected March / April 2024On…
- Company on track to initiate Phase 2 trial evaluating sabirnetug in first half of 2024 CHARLOTTESVILLE, Va., March 21,…
Four Phase 2 investigator-initiated studies of TNX-1900 (intranasal potentiated oxytocin) are ongoing for pediatric obesity, binge eating disorder, bone health…
Lead program in urea cycle disorders highlights power of CAMP4’s RAP Platform™ to increase gene expression using programmable, targeted medicines,…
CTIM-76 IND filing on track for late March 2024 Cash and cash equivalents of $14.4 million as of December 31,…
Figure 1 Dose escalation and subject numbers by dose since initiating the trial in March 2023 PYX-201 Phase 1 Part…
Medical Review Committee approved initiation of recruitment of next cohort of patients, in alignment with dose optimization protocol First patient…
LOUISVILLE, Ky., March 21, 2024 (GLOBE NEWSWIRE) -- This Women’s History Month, BrightSpring Health Services, Inc. (“BrightSpring” or the “BrightSpring…
Toronto, Ontario--(Newsfile Corp. - March 21, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer…